Founded in 2025 by Professors Chiara Ambrogio and Roberto Chiarle, Haptena is built on decades of research in molecular oncology, cancer immunology, and translational medicine. Their combined knowledge – spanning tumor genetics, resistance mechanisms, immune signaling, and therapeutic development – forms the scientific backbone of our company.

We believe that immunotherapy can deliver deeper and more durable responses when it is built around the genetic features that shape each tumor’s behavior. Our approach focuses on how oncogenic drivers – such as KRAS mutations – remodel cancer cells and their interaction with the immune system. By integrating these insights with advanced discovery platforms, we aim to develop targeted immunotherapies capable of overcoming resistance and unlocking new therapeutic opportunities for patients.